In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Something old, something new, something biobased: Designer grows a mushroom wedding gown
In the Netherlands, designer Dasha Tsapenko “grew” her wedding dress using mycelium and vintage linen lace sourced from Ukrainian flea markets.
“I wanted to combine...
Italy team develops biobased, inflammation-busting burn bandages
In Italy, a team from Istituto Italiano di Tecnologia has developed a biodegradable and biocompatible bandage using plant-based materials such as maize, pectin, and...
Swiss startup Nectariss recreates bougie fungi with fermentation
In Switzerland, a startup is recreating the intensely umami flavor of truffles, a pricey fungi that is impossible to cultivate and so difficult to...